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Abstract
Background: Acute lung injury (ALI) is a serious respiratory disorder for which therapy is primarily supportive once
infection is excluded. Surgical lung biopsy may rule out other diagnoses, but has not been generally useful for
therapy decisions or prognosis in this setting. Importantly, tissue and peripheral blood eosinophilia, the hallmarks
of steroid-responsive acute eosinophilic pneumonia, are not commonly linked with ALI. We hypothesized that
occult eosinophilic pneumonia may explain better outcomes for some patients with ALI.
Methods: Immunohistochemistry using a novel monoclonal antibody recognizing eosinophil peroxidase
(EPX-mAb) was used to assess intrapulmonary eosinophil accumulation/degranulation. Lung biopsies from ALI
patients (n=20) were identified following review of a pathology database; 45% of which (i.e., 9/20) displayed
classical diffuse alveolar damage (ALI-DAD). Controls were obtained from uninvolved tissue in patients undergoing
lobectomy for lung cancer (n=10). Serial biopsy sections were stained with hematoxylin and eosin (H&E) and
subjected to EPX-mAb immunohistochemistry.
Results: EPX-mAb immunohistochemistry provided a >40-fold increased sensitivity to detect eosinophils in the
lung relative to H&E stained sections. This increased sensitivity led to the identification of higher numbers of
eosinophils in ALI patients compared with controls; differences using H&E staining alone were not significant.
Clinical assessments showed that lung infiltrating eosinophil numbers were higher in ALI patients that survived
hospitalization compared with non-survivors. A similar conclusion was reached quantifying eosinophil
degranulation in each biopsy.
Conclusion: The enhanced sensitivity of EPX-mAb immunohistochemistry uniquely identified eosinophil
accumulation/degranulation in patients with ALI relative to controls. More importantly, this method was a
prognostic indicator of patient survival. These observations suggest that EPX-mAb immunohistochemistry may
represent a diagnostic biomarker identifying a subset of ALI patients with improved clinical outcomes.
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Background
ALI encompasses a spectrum of pulmonary disorders
that is often accompanied by life-threatening hypoxemic
respiratory failure and diffuse bilateral pulmonary infil-
trates. Moreover, the origins of ALI are often complex
(e.g., pneumonia, sepsis, or left atrial hypertension) and
not easily attributed to a defined cause [1-6]. In its most
dramatic clinical form, acute respiratory distress syn-
drome (ARDS), precipitous impairment of gas exchange
is associated with a high mortality rate (38.5%), espe-
cially among elderly patients [7]. Therapy for most
patients with idiopathic ALI is limited to supportive
care and infection prevention [6,8-10]. Select studies
have suggested a benefit of corticosteroid therapy in a
subset of patients with ALI/ARDS (e.g., [11-14]). How-
ever, large prospective studies have not supported a
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[15-18].
The pathogenesis of ALI remains unclear, largely a
consequence of the heterogeneity of patients coming
into the ICU and the broad clinical features characteris-
tic of ALI [1,19]. The cellular mechanisms contributing
to lung tissue injury in ALI are for the most part
unknown,[20] although the potential involvement of
neutrophils in the development of ALI remains the
focus of many studies (see for example [21,22]). In parti-
cular, neutrophil-derived products (e.g., extracellular
matrix degrading proteinases and reactive oxygen spe-
cies), inflammatory fibrotic cytokines, and growth fac-
tors [23-26] have been postulated as causative agents
underlying the onset and progression of disease [27].
For most patients with ALI, eosinophils have not been
reported as a prominent histological feature, despite
their potential tissue damaging capability [5,28] and
their presence in a number of other well defined pul-
monary diseases such as asthma [29] and acute eosino-
philic pneumonia [30]. However, among this larger
literature there are some studies that have implicated
this granulocyte as either a potentially important contri-
butor to disease or, at the least, a diagnostic biomarker
of events occurring in ALI patients [21,27,31]. Interest-
ingly, these studies suggested a “predictive” and “discri-
minative” value of eosinophil activity assessments in
designing an effective therapy for patients exhibiting
clinical features of ALI. Unfortunately, the lack of an
observable eosinophil infiltrate at the histological level
remains a significant confounding issue, especially for
those patients who may have been treated (even briefly)
with systemic corticosteroids. In turn, the typical
absence of visible eosinophils in most cases of ALI that
come to biopsy has limited the further development of
hypotheses and experimental studies investigating a role
(s) of eosinophils in ALI.
In this study we demonstrate that standard histologi-
cal evaluation of lung biopsies significantly underesti-
mates eosinophil accumulation when compared to
assessments using a novel eosinophil peroxidase (EPX)-
specific monoclonal antibody (EPX-mAb)v i s u a l i z e db y
immunohistochemistry. We employed this unique
increase in sensitivity to detect eosinophils and evidence
of tissue degranulation in a group of ALI patients. A
retrospective assessment of ALI patients who had a lung
biopsy taken during the course of their acute care was
conducted, comparing the results of these assessments
with lung tissue from control subjects. These blinded
assessments revealed that the added sensitivity of EPX-
mAb immunohistochemistry detected a significant
increase in eosinophil accumulation/degranulation in
ALI vs. control subjects. More importantly, EPX-mAb
immunohistochemistry identified a subset of ALI
patients who survived hospitalization, suggesting its use
a sap r o g n o s t i ci n d i c a t o rm a yr e p r e s e n tap r e v i o u s l y
underappreciated diagnostic strategy in the management
of pulmonary patients.
Methods
IRB
The patient studies presented in this manuscript were
performed in accordance with NIH guidelines and Mayo
Foundation institutional policies (Institutional Review
Board, 08-001908 Immunohistochemical Study of Eosi-
nophil Degradation in Archived Lung Biopsies), and in
compliance with HIPPA guidelines for patient privacy.
Study Subjects
An overview of the demographic data and pathological/
clinical assessments of our ALI study subjects is pre-
sented in Tables 1 and 2. These pulmonary patients
were initially identified by study personnel from a search
of the Mayo Clinic Arizona Pathology Database with the
search key words: lung, biopsy, acute lung injury (ALI),
diffuse alveolar damage (DAD), organizing pneumonia,
and ARDS. Study personnel subsequently reviewed the
available pathology reports and clinical medical records
to identify the subset of patients who had received a
diagnosis of ALI. Thus, to be included in this study a
given patient had to have a diagnosis of ALI and have
undergone a biopsy during their course of treatment. It
is noteworthy, that this process was not discriminatory
and all patients with available biopsy material that had
received an ALI diagnosis as part of their standard-of-
care were included in this study. The ALI patients
included in this study met AECC established clinical cri-
teria [4] for an acute lung injury diagnosis and also dis-
played characteristic pathological changes linked with
this disease. Specifically, assessments of all study
patients upon admission with acute respiratory distress
revealed the presence of diffuse radiographic abnormal-
ities and hypoxia characterized by an A-a gradient
(PaO2/FiO2) less than 300 [4,32]. Indeed, the PaO2/
FiO2 ratio in a subset of these cases (11 of 20 total
cases) was below 150 and thus would meet clinical cri-
teria for ARDS [4,32]. In addition, the twenty ALI
patients in this study included thirteen patients (inde-
pendent of PaO2/FiO2 levels) that required mechanical
ventilation during their hospitalization. Review of patient
medical records also revealed the absence of typical risk
factors associated with ALI, including myocardial infarc-
tion, pulmonary embolism, infection/sepsis (e.g., pneu-
monia), and acute drug reaction. The pathology
evaluations of all study-subjects confirmed the clinical
indications of ALI. That is, each patient included in our
study displayed three specific histopathologies in the
available biopsies [33]: (i) T h ep r e s e n c eo ff i b r i ni nt h e
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monia (i.e., a prominent airway cellular infiltrate); and
(iii) Evidence of reactive airway epithelial Type II cell
hyperplasia. Among these twenty ALI patients, 45% (i.e.,
9/20) displayed classical diffuse alveolar damage (ALI-
DAD). Seven of the study group did not survive hospita-
lization, and of these non-surviving patients >71% (5/7)
received an ALI-DAD diagnosis. A variety of co-morbid
medical disorders were evident in our ALI patients,
including several patients with connective tissue disor-
ders. However, examination of the medical records and
care-giver notes failed to identify elements of common-
ality regarding disease onset or progression. Nonethe-
less, the unresolved character of disease progression in
these subjects was such that nineteen of the twenty
patients received corticosteroid therapy during their
course of treatment.
Control lung samples consisted of uninvolved areas of
lung tissue recovered from patients undergoing resec-
tion for a diagnosis of lung cancer (Table 1). None of
the control subjects were receiving systemic corticoster-
oids, although four control subjects were receiving
inhaled corticosteroids.
Recovery and processing of bronchial tissue biopsies
The twenty lung specimens obtained from patients with
ALI included sixteen surgical lung biopsies and four
transbronchial lung biopsies considered adequate for
histologic review (i.e., containing alveolated lung par-
enchyma). All control biopsies were taken from unin-
volved areas of surgically resected lung tissue removed
for treatment of lung cancer. Lung tissue biopsies were
f i x e di n4 %b u f f e r e df o r m a l i n ,e m b e d d e di np a r a f f i n ,
and serial 4 μm thick sections were cut.
Table 1 Demographic Data on Control and Acute Lung Injury (ALI) Study Subjects
Study Subjects Age Smoking History (Pack - Years) Gender
Male (M) Female (F)
Acute Lung Injury 64.0 ± 2.6 21.1 ± 5.3 11 9
Controls 68.4 ± 4.5 35.2 ± 13.6 3 7
Table 2 Clinical Characterization of Patients with Acute Lung Injury
Patient Concurrent Clinical Diagnoses Gender Age PaO2/FIO2 Ventilator Hospital Death Pathology Diagnosis
1 Esophageal carcinoma M 51 80 Yes Yes ALI
2 SLE F 73 290 No No ALI
3 Dressler’s syndrome M 72 134 Yes Yes ALI
4 Lymphoma F 63 204 Yes No ALI
5 Crohn’s Disease F 63 205 No No ALI with possible AEP
6 HIV+ M 64 150 Yes No ALI-DAD With PCP
7 Multiple myeloma F 73 111 Yes No ALI-DAD
8 Lung cancer F 65 100 Yes No ALI-DAD
9 Hepatitis C M 41 89 Yes Yes ALI-DAD
10 SLE F 75 156 Yes Yes ALI-DAD
11 MCTD/pulmonary fibrosis M 65 93 Yes Yes ALI-DAD
12 Dematomyositis F 42 149 No Yes ALI-DAD
13 SLE M 77 200 No No ALI
14 Pneumoconiosis M 69 66 Yes No ALI
15 Drug-induced lung toxicity M 61 223 No No ALI with fibrosis
16 Esophageal carcinoma M 67 96 Yes No ALI-DAD
17 RZ/possible aspiration F 72 205 No No ALI
18 CVD F 41 167 No No ALI-DAH
19 Goodpasture syndrome M 72 133 Yes Yes ALI-DAD with HSV infection
20 Wegener syndrome M 73 205 No No ALI with fibrosis
Table Abbreviations: AEP- Acute Eosinophilic Pneumonia; ALI Acute- Lung Injury; ALI-DAD- Acute Lung Injury which includes Diffuse Alveolar Damage; ALI-DAH-
Acute Lung Injury which includes Diffuse Alveolar Hemorrhage; CVD- undifferentiated Collagen Vascular Disorder; DAD Diffuse Alveolar Damage; DAH- Diffuse
Alveolar Hemorrhage; HIV Human Immunodeficiency Virus; MCTD- Mixed Connective Tissue Disorder; PCP Pneumocystis Pneumonia; RA- Rheumatoid Arthritis;
SLE Systemic Lupus Erythematosus
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Page 3 of 10Histopathological and immunohistochemical staining of
lung tissue sections
H&E staining was performed using an automated stain
processing unit in the Mayo Clinic Arizona clinical his-
tology unit. Immunohistochemistry was performed using
a EPX-mAb as previously described [34]. Evaluations of
the slides were performed with either an Olympus BX50
or a Zeiss Axiophot compound microscope.
Histopathological evaluation of patients and the
quantification of EPX-mAb immunohistochemistry
Serial sections from each biopsy were coded by clinical
histopathology laboratory personnel and in each case the
middle (slide 2) of the three serial sections was stained
with Hematoxylin - Eosin (H&E). Slide 1 of the series
was subjected to immunohistochemical staining with
EPX-mAb and slide 3 served as an isotype immunoglo-
bulin negative control for the immunohistochemistry.
The eosinophil infiltration of lung tissue using H&E
staining was performed in an investigator-blinded fash-
ion independently by an experienced pulmonary pathol-
ogist with a specialty in lung diseases (KL) and a
pathology resident (PG). The slides were evaluated by
each individual as a numerical average calculated from
10 randomly selected hpf (high powered fields; 40x
objective/10x ocular lens, 0.29 mm
2 field of view); that
is, a total area of ~3 mm
2 per biopsy-investigator. The
reported values are the mean ± SEM of all investigator-
derived counts.
Quantification of eosinophil tissue infiltration within
each biopsy using EPX-mAb immunohistochemistry was
independently performed in an intra/inter-blinded fash-
ion that included investigators from pathology (KL, EJ,
and PG - EPX-mAb based eosinophil counts in lung tis-
sue); KL and EJ - EPX-mAb assessments of eosinophil
degranulation), a hospital/clinic-based pulmonary fellow
(KP - EPX-mAb based eosinophil counts in lung tissue),
and a PhD graduate research fellow (LW - EPX-mAb
based eosinophil counts and degranulation in lung tis-
sue). All evaluations were done at a magnification of
400x. The number of positively stained eosinophils was
determined in the alveolar lung parenchyma as a
numerical average calculated from 10 randomly selected
hpf; that is, a total area of ~3 mm
2 per biopsy-investiga-
tor. The reported values are the mean ± SEM of investi-
gator-derived counts.
The level and extent of eosinophil degranulation
observed within each patient biopsy was also determined
by scanning 10 randomly selected hpf (40x objective/10x
ocular lens, 0.29 mm
2 field of view); that is, a total area
of ~3 mm
2 per biopsy-investigator. Each field examined
was graded using a scale that permitted stratifying the
available patients based on a relatively low resolution
grading scale that was easily reproduced by multiple
evaluators of varying levels of experience and expertise:
Level 0 = No identifiable eosinophils and/or degranula-
tion [35]; Level 1a = The field shows evidence of eosino-
phil degranulation (i.e., extracellular release of EPX) that
represents ≤10% of the field’s total area and has <3 inde-
pendent areas within the field displaying degranulation;
Level 1b = The field shows similar evidence of eosino-
phil degranulation as Level 1a but instead displays ≥3
independent areas within the field with evidence of
degranulation; Level 2a = The field shows evidence of
eosinophil degranulation that includes extracellular
release of EPX, enucleated eosinophils (i.e., cytoplasmic
fragments), and/or the presence of free eosinophil gran-
ules. The extent of degranulation represents 10 - 50% of
the field’s total area; Level 2b = The field shows similar
evidence of eosinophil degranulation as Level 2a but
instead has a level of degranulation representing >50%
of the field’s total area. Eosinophil degranulation was
quantified for each of 10 randomly selected hpf of a
given biopsy (i.e., patient) by initially applying an
increasing numerical value to the level of degranulation
evident in the field (Level 0 = 0, Level 1a = 1, Level 1b
= 2, Level 2a = 3, and Level 2b = 4). The extent of eosi-
nophil degranulation in the biopsy was then determined
as the average of the numerical values assigned to each
of the 10 hpf examined. This grading of eosinophil
degranulation was performed independently by three
outcome-blinded evaluators (an experienced pulmonary
pathologist (KL), a pathology resident-fellow (EM), and
a Ph.D. graduate student (LW)), all of whom were also
unaware of the scores reported by the other evaluators.
Degranulation scores are reported as the mean numeri-
cal value derived from all three evaluators ± SEM.
Statistical Analysis
Data are expressed as the mean ± SEM. Statistical analy-
sis for comparisons between groups was performed
using either a Student’s T test or a Wilcoxon Two-Sam-
ple Test for non-parametric data for comparisons
between data sets that were not uniformly distributed.
Differences between mean values were considered signif-
icant when p < 0.01. Intraclass correlation coefficients
(ICC) were also determined between investigators read-
ing slides as a measure of inter-rater agreement [36].
Results
EPX-mAb immunohistochemistry provides an enhanced
level of sensitivity for the detection of eosinophils
infiltrating lung biopsies
Serial biopsy sections from either control or ALI sub-
jects were stained for evaluations of eosinophil tissue
infiltration. Representative photomicrographs of H&E
stained slides as well as lung sections subjected to EPX-
mAb immunohistochemistry are shown in Figure 1. The
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staining methods are presented as individual patient
assessments in the histograms of Figure 2. As expected,
the evaluation of the H&E stained patient biopsies
revealed little evidence of eosinophil infiltration in both
control and ALI subjects (0.02 infiltrating eosinophils/
hpf and 0.04 infiltrating eosinophils/hpf, respectively).
However, evaluation by the same pathology investigators
of the serial slides subjected to EPX-mAb immunohisto-
chemistry demonstrated an enhanced sensitivity to
detect eosinophils in these lung tissue sections. Specifi-
cally, evaluations of the lungs of control subjects using
EPX-mAb immunohistochemistry revealed a >40-fold
increase in the ability to detect tissue infiltrating eosino-
phils relative to H&E staining (0.81 eosinophils/hpf vs.
0.02 eosinophils/hpf, p < 0.01).
Eosinophil infiltration of the pulmonary parenchyma is
higher in ALI patients compared to control subjects and
is a diagnostic indicator of patient survival
Evaluation of serial lung sections following EPX-mAb
immunohistochemistry demonstrated that the density of
pulmonary eosinophils in the collective group of ALI
patients is significantly higher relative to control sub-
jects (3.6-fold, 2.88 eosinophils/hpf vs. 0.81 eosinophils/
hpf (p < 0.01), respectively). More importantly, further
evaluations of the ALI patients (Figure 2, shaded histo-
grams) surprisingly showed that EPX-mAb detection of
infiltrating lung eosinophils divided these patients into
subjects which survived vs. those that did not survive
hospitalization (8.4 ±2.9 eosinophils/hpf vs.1 . 9±0 . 6
eosinophils/hpf, p < 0.01).
ALI patients surviving hospitalization display significant
levels of eosinophil degranulation (i.e., extracellular
matrix deposition of EPX) compared with non-surviving
patients
Assessments of lung sections following EPX-mAb
immunohistochemistry revealed that ALI patients dis-
played significant and varying levels of degranulation
that were quantifiable. This degranulation was often
observed in these patients in the absence of identifiable
intact eosinophils. The photomicrographs of Figure 3
are representative of the stratified levels of increasing
degranulation observed in ALI patients from no evi-
dence of degranulation (Level 0)i nag i v e nh i g h
Figure 1 EPX-mAb immunohistochemistry represents a sensitive and novel strategy relative to H&E staining for the detection of
infiltrating eosinophils as well as evidence of eosinophil degranulation in the pulmonary parenchyma. Side-by-side comparisons of serial
lung sections stained with H&E and sections subjected to EPX-mAbimmunohistochemistry (red staining cells and extracellular matrix areas) are
presented from control subjects and an ALI patient. Scale bar = 50 μm.
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degranulation (Level 2b). Similar to the higher levels of
eosinophil infiltration observed in the collective group
of ALI patients, the collective group also evidenced a
>2-fold increase in the level of eosinophil degranulation
compared to control subjects (2.20 ± 0.15/hpf vs.1 . 0 2±
0.38/hpf, respectively). More importantly, quantitative
assessments of degranulation (i.e., mean numerical score
±SEM) based on EPX-mAb immunohistochemistry
(Table 3 and Figure 4) revealed that ALI patients surviv-
ing their hospitalization also displayed significantly
higher levels of degranulation compared to non-surviv-
ing patients (2.62 ± 0.18/hpf vs. 1.58 ± 0.10/hpf,
respectively).
Discussion
Independent of any conclusions regarding our evaluation
of ALI vs. control subjects, two technical observations
regarding our assessments of the lung biopsies using
EPX-mAb immunohistochemistry relative to H&E stain-
ing are noteworthy: (i) EPX-mAb immunohistochemistry
is an easily performed assessment that provided a >40-
fold enhancement to detect tissue infiltrating eosinophils.
This increased sensitivity not only allowed for the greater
detection of tissue infiltrating eosinophils but also
corresponding increases in the speed, accuracy, and
reproducibility of this determination. (ii) EPX-mAb
immunohistochemistry provided a rapid and definitively
quantitative assessment of eosinophil degranulation
within the lung parenchyma, observable even in the
absence of intact infiltrating eosinophils.
Unfortunately, studies of ALI patients are often
incomplete and subject to ambiguities resulting from
the broad and complex character of symptoms and con-
tributing etiologies [2,37]. Compounding these issues are
the limited sample materials that are available for analy-
sis (e.g., lung tissue or BAL fluid), including the timing
of when the samples were recovered during the course
of a given patient’s care. In this respect, the study pre-
sented here is subject to these very same limitations.
That is, our study is of a small heterogeneous cohort of
patients (n=20) whose disease origins and severity vary
Figure 2 Assessment of individual patient biopsies revealed that unlike traditional H&E histopathology, EPX-mAb
immunohistochemistry demonstrated that ALI patients have increased levels of eosinophils relative to control subjects and that
within the ALI cohort this increase correlated with patient survival. Serial sections from either control subjects or acute lung injury patients
were stained with H&E and subjected to EPX-mAb immunohistochemistry prior to evaluation for infiltrating eosinophil numbers per high
powered field. Eosinophil counts per hpf were determined by individual investigators (n=2) as the average count resulting from the
examination of 10 randomly selected fields; investigators were blinded to both the clinical outcome and the scores of the fellow evaluator. The
scatter plots presented represent values for each individual patient derived as the mean of the average eosinophil counts from these evaluators
(ICC = 0.785 (95% confidence interval: 0.540 to 0.908). The scatter plots within the shaded area represent acute lung injury patients following
EPX-mAb immunohistochemistry that were then stratified (following decoding of the data) on the basis of their hospital survival. The mean for
each cohort is presented as a horizontal bar. *p < 0.01
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Page 6 of 10considerably. Moreover, we did not have control over
the general demographics of these ALI patients nor
could we dictate why, when, or where within the lung
the biopsies for study were taken relative to the course
of disease and/or patient treatment. The ALI subjects of
this study were also not selected on the basis of a
defined and standardized medical history or a regimen-
ted treatment plan. Finally, the control subjects available
to us were limited and did not include healthy volunteer
biopsies or ALI patients prior to any medical
interventions.
Given the limitations of the ALI study group and our
control subjects noted above, we were surprised at the
ability of EPX-mAb immunohistochemistry to distin-
guish ALI patients from control subjects. Specifically,
eosinophils are not considered a reliable histopathologi-
cal marker of ALI (reviewed in [5,28]). Yet in a comple-
tely patient-blinded fashion that was reproducible
among 3-4 independent evaluators who had no knowl-
edge of one another’s assessments, our numerical results
were able to identify a group of ALI patients relative to
control subjects on the a basis of both increased
numbers of tissue infiltrating eosinophils and increased
levels of eosinophil degranulation. Furthermore, these
evaluations allowed us in a completely clinical outcome-
blinded fashion to stratify the ALI patients into those
surviving their hospitalization relative to the non-surviv-
ing patients. It is clear that the design and power of this
study precludes us from overly provocative conclusions
regarding the role of eosinophils, including their link
with specific symptoms or their part in pathways that
exacerbate or attenuate disease pathologies. Nonetheless,
this study does suggest that EPX-mAb immunohisto-
chemistry may represent a previously unrecognized
diagnostic tool providing prognostic information for the
management of ALI patients. In addition, given the pau-
city of available therapeutic options and discriminatory
testing modalities, [1,6,8,10,19] assays detecting the
release of eosinophil products (e.g., ELISA based assess-
ment of degranulation from biological fluids such as
breath condensate, intratracheal tube secretions, and/or
BAL fluid) may also represent rapid and minimally inva-
sive biomarkers of disease to assess this difficult patient
population [38]. Indeed, this initial report provides the
Figure 3 Acute Lung Injury patients display quantitatively different levels of eosinophil degranulation that may occur even in the
absence of intact infiltrating eosinophils. Representative photomicrographs of the five described levels of eosinophil degranulation within
biopsies from ALI patients. Level 0: No evidence of eosinophil degranulation. Level 1a: Nominal levels of eosinophil degranulation representing
<3 areas of granule protein release that is <10% of the field of view. Level 1b: Slightly elevated level of eosinophil degranulation representing
≥3 areas of granule protein release that again is <10% of the field of view. Level 2a: Significant level of eosinophil degranulation that includes
10-50% of the field of view. Level 2b: Significant level of eosinophil degranulation that includes extracellular release of EPX, enucleated
eosinophils (i.e., cytoplasmic fragments), and/or the presence of free granules (i.e., EPX-containing secondary granules not associated with
fragmented eosinophils). The extent of degranulation represents >50% of the field’s total area. Scale bar = 50 μm.
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plexity to expand this link between ALI patients and
their survival based on evidence of pulmonary eosino-
phils and tissue degranulation.
Conclusions
The studies presented in this report have identified both
significant technical insights and revelations regarding
eosinophils in lung biopsy samples from control and
ALI patients. These observations will likely have a direct
impact on the assessment of eosinophils and their role
(s) in lung diseases and, more important, may lead to
previously overlooked or untried diagnostic and
therapeutic strategies with which to treat these proble-
matic patients.
￿ Immunohistochemical detection of EPX in lung tis-
sue biopsies provides even a board certified pathologist
(with a specialty in pulmonary diseases) a >40-fold
increase in sensitivity to detect tissue infiltrating eosino-
phils in lung tissue sections
￿ EPX-mAb based immunohistochemistry allows for
the unique assessment of eosinophil activation (i.e.,
degranulation events) within the lung even in the
absence of a demonstrable eosinophil infiltrate
￿ The increased sensitivities afforded by EPX-mAb
demonstrate that increases in lung infiltrating
Table 3 Eosinophil Degranulation Scores Derived from EPX-mAb Immunohistochemistry Algorithm
Pulmonary Patients Eosinophil Degranulation Scores Mean ±SEM
PhD Graduate Student
(LW)
Pathology Fellow
(EJ)
Board-certified Pulmonary
Pathologist (KL)
Non-involved Lung Tissue from Otherwise
“Healthy” Control Subjects
2.3 0 2.0 1.43 0.72
2.0 0.8 1.9 1.57 0.38
1.2 0 1.3 0.83 0.42
1.4 0 1.3 0.90 0.45
1.2 0 1.4 0.87 0.44
1.2 0.2 1.1 0.83 0.32
1.5 1 1.2 1.23 0.15
1.2 0 1 0.73 0.37
1.2 0.4 1.3 0.97 0.28
1.2 0.2 1 0.80 0.31
Acute Lung Injury (ALI)
Subjects
Surviving Patients 2.4 2.7 2.7 2.61 0.10
2.0 2.2 2.5 2.23 0.15
3.2 4.0 4.1 3.77 0.28
1.8 2.8 2.5 2.37 0.30
2.6 2.3 2.6 2.50 0.10
2.4 3.7 2.9 3.00 0.38
2.5 2.6 2.2 2.43 0.12
1.1 1.1 1.4 1.20 0.10
3.8 3.9 3.6 3.77 0.09
3.1 3.2 3.3 3.20 0.06
2.2 3.3 2.9 2.80 0.32
1.8 1.2 1.7 1.57 0.19
Non-surviving
Patients
1.2 1.1 1.7 1.33 0.15
1.8 2.0 1.9 1.90 0.05
1.5 1.2 1.0 1.23 0.12
1.1 1.2 1.0 1.10 0.05
2.0 1.9 2.3 2.07 0.10
2.7 2.4 1.7 2.27 0.24
1.4 1.2 1.4 1.33 0.05
1.4 1.4 1.3 1.37 0.03
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Page 8 of 10eosinophils and evidence of eosinophil degranulation are
surprisingly characteristic features of biopsies from ALI
patients relative to control subjects
￿ Assessments of lung biopsies from ALI patients fol-
lowing EPX-mAb immunohistochemical staining may
p r o v i d eap o t e n t i a lb a s i st oi d e n t i f yas u b s e to ft h e
~40% of ALI patients who will not survive their
hospitalization.
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